Back to Journals » Therapeutics and Clinical Risk Management » Volume 14

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma

Total article views   HTML views PDF downloads Totals
23,688 Dovepress* 13,548+ 2,185 15,733
PubMed Central* 10,140 1,728 11,868
Totals 23,688 3,913 27,601
*Since 31 May 2018
Total mentioned Facebook Delicious Reddit Twitter Others
5 0 0 0 1 4

View citations on PubMed Central and Google Scholar